We are pleased to announce that the first paper related to study of our Patient-Derived Tumor Xenograft (PDTX) models, entitled „Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets” is now published in the journal Cells. In this research, our PDTX melanoma model was used to model acquired vemurafenib resistance in a BRAF V600E mutant genetic background. KINETO Lab’s model was able to identify novel expressional changes that drive therapy failure thus might be targeted to improve the efficacy.

The publication can be accessed under the following link.